Thomas Reid, MD
Ophthalmology · Bishop, CANPI 1871530907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $517 of the $615 with a category attached, or 84.1%. Alcon accounts for 62.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $315 and has fallen 91.7% since, to $26 in 2025. That places this record below the midpoint for ophthalmology clinicians in CA, where the typical reported total is $1,218.
Across 19 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$381
- Mallinckrodt Hospital Products Inc.$197
- Carl Zeiss Meditec USA, Inc.$19
- Lilly USA, LLC$17
What the payments were for
- Food & beverage$51784%
- Education$9816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $381 |
| Mallinckrodt Hospital Products Inc. | 5 | $197 |
| Carl Zeiss Meditec USA, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
How this compares
$615 in reported general payments places this provider in the 35th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 22 | $8,925 |
| Prednisolone Acetate | 221 | $7,459 |
| Cyclosporine | 19 | $4,788 |
| Ketorolac Tromethamine | 195 | $4,731 |
| Brimonidine Tartrate | 56 | $4,273 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $3,638 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $3,465 |
| MoxifloxacinMoxifloxacin Hcl | 192 | $3,188 |
| Alphagan PBrimonidine Tartrate | 11 | $2,762 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 28 | $2,487 |
| Latanoprost | 286 | $2,241 |
| Timolol Maleate | 130 | $964 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $477 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Bishop
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.